This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT. - eVOLVE Cervical

Hibi Kazushige0 个研究点目标入组 80 人开始时间: 2023年11月7日最近更新: 2023年11月20日

试验速览

阶段: 3 期
状态: 招募中
发起方
入组人数: 80

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 15age old 至 ot applicable（—）
性别: Female

入选标准

•For inclusion in the study, patients should fulfill the following criteria:
•1. Female.
•2. Aged at least 15 years at the time of screening.
•3. Body weight > 35 kg.
•4. Histologically documented FIGO 2018 Stage IIIC to IVA cervical adenocarcinoma, cervical squamous carcinoma, or cervical adenosquamous carcinoma, with lymph node involvement.
•5. Initial staging procedures performed no more than 42 days prior to the first dose of CCRT.
•6. Provision of tumor sample to assess the PD-L1 expression.
•7. Must not have progressed following CCRT, participants with persistent disease after definitive CCRT must not be amenable to other available therapies with curative intent.
•8. WHO/ECOG performance status of 0 or 1.
•9. Adequate organ and bone marrow function.
•10. Capable of providing signed informed consent.

排除标准

•Patients should not enter the study if any of the following exclusion criteria are fulfilled:
•1. Diagnosis of small cell (neuroendocrine) or mucinous adenocarcinoma of cervical cancer.
•2. Evidence of metastatic disease.
•3. Intent to administer a fertility-sparing treatment regimen.
•4. History of organ transplant.
•5. Active or prior documented autoimmune or inflammatory disorders.
•6. Uncontrolled intercurrent illness.
•7. History of another primary malignancy except for a) Malignancy treated with curative intent with no known active disease 2 years or more before the first dose of study intervention; b) Adequately treated nonmelanoma skin cancer or lentigo maligna, or carcinoma in situ without evidence of disease.
•8. Unresolved toxicities from previous CCRT except for irreversible toxicity that is not reasonably expected to be exacerbated.
•9. Prior history or presence of vesicovaginal, colovaginal, or rectovaginal fistula.
•10. History of anaphylaxis to any biologic therapy or vaccine.
•11. Current or prior use of immunosuppressive medication within 14 days before the first dose of the study intervention is excluded. The following are exceptions to this criterion: a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular injection); b) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication or chemotherapy premedication) or a single dose for palliative purpose (eg, pain control).
•12. Patients who have undergone a previous hysterectomy, including a supracervical hysterectomy, or will have a hysterectomy as part of their initial cervical cancer therapy.
•13. Any prior (besides prior CCRT) or concurrent treatment for cervical cancer.
•14. Major surgical procedures within 4 weeks prior to the first dose of the study intervention or still recovering from prior surgery.
•15. Exposure to immune mediated therapy prior to the study for any indication.
•16. Receipt of live attenuated vaccine within 30 days prior to the first dose of the study intervention.
•17. Participants with a known allergy or hypersensitivity to the study intervention, or any excipients of the study intervention.

研究者

发起方

Hibi Kazushige

相似试验

进行中（未招募）

1 期

A study investigating copanlisib in combination with standard treatment versus standard treatment alone in order to see if copanlisib improves the response to standard treatment in patients with relapsed indolent non-Hodgkin's lymphoma.Patients with relapsed indolent non-Hodgkin's lymphomaMedDRA version: 20.0Level: PTClassification code 10029600Term: Non-Hodgkin's lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001088-38-CZBayer AG520

进行中（未招募）

1 期

A study investigating copanlisib in combination with standard treatment versus standard treatment alone in order to see if copanlisib improves the response to standard treatment in patients with relapsed indolent non-Hodgkin's lymphoma.Patients with relapsed indolent non-Hodgkin's lymphomaMedDRA version: 21.1 Level: PT Classification code 10029600 Term: Non-Hodgkin's lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001088-38-SKBayer AG520

进行中（未招募）

1 期

A study investigating copanlisib in combination with standard treatment versus standard treatment alone in order to see if copanlisib improves the response to standard treatment in patients with relapsed indolent non-Hodgkin's lymphoma.Patients with relapsed indolent non-Hodgkin's lymphomaMedDRA version: 20.0 Level: PT Classification code 10029600 Term: Non-Hodgkin's lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001088-38-ATBayer AG520

进行中（未招募）

1 期

EUCTR2015-001088-38-HUBayer AG520

进行中（未招募）

1 期

A study investigating copanlisib in combination with standard treatment versus standard treatment alone in order to see if copanlisib improves the response to standard treatment in patients with relapsed indolent non-Hodgkin's lymphoma.Patients with relapsed indolent non-Hodgkin's lymphomaMedDRA version: 23.0Level: PTClassification code 10029600Term: Non-Hodgkin's lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001088-38-BGBayer AG520